Evaluating role of Adaptive radiotherapy in head neck cancers in reducing salivary gland toxicity
- Conditions
- Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
- Registration Number
- CTRI/2018/08/015531
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Biopsy proven Squamous cell carcinoma of the oropharynx, hypopharynx and larynx.
2.AJCC stage T1-3, N0-2c, M 0.
3.KPS >= 70.
4.Age >=18 and <= 70 years.
5.Patient willing and reliable for follow-up.
6.Patientâ??s nutritional & physical condition compatible with planned therapy.
7.Signed study specific consent form.
1.T1-2 N0 M0 of Vocal cords
2.History of surgery for the primary or node in head and neck.
3.Evidence of distant metastases or N3 nodal stage.
4.Previous therapeutic irradiation for head & neck cancer.
5.Patients who have received neoadjuvant chemotherapy.
6.Active untreated infection, which preclude the use of systemic chemotherapy or would interfere with completion of treatment.
7.Any histopathology other than Squamous Carcinoma.
8.Primary nasopharyngeal or paranasal sinus cancers.
9.Pregnancy or lactating women.
10.Previous history of malignancy within 5 years.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method